Advances in opioid therapy and formulations

Supportive Care in Cancer

Volumn 13, Issue 3, 2005, Pages 138-144

  Walsh, Declan ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Dosing strategies; Drug delivery systems; Formulations; Opioids

Indexed keywords

ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; FENTANYL; HYDROMORPHONE; LIPOSOME; METHADONE; MORPHINE; MORPHINE SULFATE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; OXYCODONE; OXYMORPHONE; PETHIDINE; SUFENTANIL;

ANALGESIA; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; EPIDURAL ANESTHESIA; HALLUCINATION; HUMAN; MENTAL DISEASE; MINIPUMP; MYOCLONUS; NAUSEA; NIGHTMARE; OSMOTIC PUMP; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT SATISFACTION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, CUTANEOUS; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HUMANS; INFUSION PUMPS, IMPLANTABLE; MALE; MORPHINE; NEOPLASMS; OXYCODONE; PAIN MEASUREMENT; PAIN, INTRACTABLE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 16344383698     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0743-x     Document Type: Review

References (49)

1. Daut RL, Cleeland CS (1982) The prevalence and severity of pain in cancer. Cancer 50:1913-1918
2. Expert Working Group of the European Association for Palliative Care (1996) Morphine in cancer pain: modes of administration. BMJ 312:823-826
3. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542-2554
4. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587-593
5. Bruera E, Belzile M, Pituskin E, Faisinger R, Darke A, Harsanyi Z, Babul N, Ford I (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16:3222-3229
6. Galer BS, Coyle N, Pasternak GW, Portenoy RK (1992) Individual variability in the response to different opioids: report of five cases. Pain 49:87-91
7. Ripamonti C, Dickerson ED (2001) Strategies for the treatment of cancer pain in the new millennium. Drugs 61:955-977
8. de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378-384
9. Gourlay GK, Cherry DA, Cousins MJ (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25:297-312
10. Warfield CA (1998) Controlled-release morphine tablets in patients with chronic cancer pain: a narrative review of controlled clinical trials. Cancer 82:2299-2306
11. Hanks GW (1989) Controlled-release morphine (MST Contin) in advanced cancer. The European experience. Cancer 63:2378-2382
12. Cundiff D, McCarthy K, Savarese JJ, Kaiko R, Thomas G, Grandy R, Goldenheim P (1989) Evaluation of a cancer pain model for the testing of long-acting analgesics. The effect of MS Contin in a double-blind, randomized crossover design. Cancer 63:2355-2359
13. Broomhead A, Kerr R, Tester W, O'Meara P, Maccarrone C, Bowles R, Hodsman P(1997) Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 14:63-73
14. Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R (2003) Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84-92
15. Gimbel JS, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60:927-934
16. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105:71-78
17. Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, Rutstein J, Lacouture PG (2000) Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 160:853-860
18. Cheville A, Chen A, Oster G, McGarry L, Narcessian E (2001) A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. J Bone Joint Surg Am 83-A:572-576
19. Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73:37-45
20. Mucci-LoRusso P, Herman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2:239-249
21. Davis MP (2003) Equianalgesia - paradox and pitfalls. J Terminal Oncol 2:89-91
22. Payne R (1998) Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol 25:47-53
23. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E (2001) Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322:1154-1158
24. Sloan PA, Moulin DE, Hays H (1998) A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 16:102-111
25. Mystakidou K, Befon S, Tsilika E, Dardoufas K, Georgald S, Vlahos L (2002) Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. Oncology 62:9-16
26. Wong JO, Chiu GL, Tsao CJ, Chang CL (1997) Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 35:25-32
27. Beaver WT, Wallenstein SL, Houde RW, Rogers A (1977) Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 17:186-198
28. Gabrail NY, Dvergsten C, Ma T, Frailey A, Ahdieh H (2003) Oxymorphone extended release (ER) in opioid rotation. Presented at the 15th MASCC International Symposium; June 18-21, 2003; Berlin, Germany [A-36]. Support Care Cancer 11:396
29. Sloan P (2002) Analgesic safety and efficacy of extended release oxymorphone for the treatment of cancer pain. Support Care Cancer 10:360
30. Sinatra RS, Lodge K, Sibert K, Chung KS, Chung JH, Parker A, Jr, Harrison DM (1989) A comparison of morphine, meperidine, and oxymorphone as utilized in patient-controlled analgesia following cesarean delivery. Anesthesiology 10:585-590
31. Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18:83-13
32. Endo/Penwest (2003) Oxymorphone - EN 3202, EN 3203. Drugs R D 4:204-206
33. McIlwain H, Burch F, Frailey A, Ma T, Ahdieh H (2003) Oxymorphone extended-release offers long-term safety, effectiveness, and dose stabilization in osteoarthritis pain: results of a one-year interim report. Presented at the American Pain Society 22nd Annual Scientific Meeting; March 20-23, 2003; Chicago, IL [poster 908]
34. Slatkin N (2003) Long-term safety, efficacy, and dose stabilization of oxymorphone ER in cancer pain. Support Care Cancer 11:397
35. Durect Corporation (2001) DUROS technology platform. Fact sheet. Cupertino, CA
36. Howell SB (2001) Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J 7:219-227
37. Yaksh TL, Provencher JC, Rathbun ML, Myers RR, Powell H, Richter P, Kohn FR (2000) Safety assessment of encapsulated morphine delivered epidurally in a sustained-release multivesicular liposome preparation in dogs. Drug Deliv 7:27-36
38. Crews JC (1990) Epidural opioid analgesia. Crit Care Clin 6:315-342
39. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Català E, Bryce DA, Coyne PJ, Pool GE (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040-4049
40. Wright PM, O'Toole DP, Barron DW (1992) The influence of naloxone infusion on the action of intrathecal diamorphine: low-dose naloxone and neuroendocrine responses. Acta Anaesthesiol Scand 36:230-233
41. Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER (1999) Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology 90:1007-1011
42. Donnelly S, Davis MP, Walsh D, Naughton M (2002) Morphine in cancer pain management: a practical guide. Support Care Cancer 10:13-35
43. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38
44. Kochhar R, LeGrand SB, Walsh D, Davis MP, Lagman R, Rivera NI (2003) Opioids in cancer pain: common dosing errors. Oncology 17:571-575
45. Walsh D (2000) Pharmacological management of cancer pain. Semin Oncol 27:45-63
46. Brant JM (2001) Opioid equianalgesic conversion: the right dose. Clin J Oncol Nurs 5:163-165
47. Blumstein HA, Moore D (2003) Visual analog pain scores do not define desire for analgesia in patients with acute pain. Acad Emerg Med 10:211-214
48. Reyes-Gibby CC, McCrory LL, Cleeland CS (2003) Variations in patients' self-report of pain by treatment setting. J Pain Symptom Manage 25:444-448
49. Walsh D, Rivera NI, Davis MP, Lagman R, LeGrand SB (2004) Strategies for pain managment: Cleveland Clinic Foundation Guidelines for opioid dosing for cancer pain. Support Care Cancer 1:157-164